Vertex Releases Findings in Type 1 Diabetes Trial

NEC member Vertex Pharmaceuticals recently announced some of the findings within their Type 1 diabetes trial after receiving the test results from one of its patients. The company was encouraged by the results and publicized their findings, in what Vertex’s Executive Chairman, Jeff Leiden called a “medical milestone.”

The patient is one of the first to receive this treatment as the trial involves only 16 patients. The diabetic patient was injected with stem cells that have been converted into insulin-producing islet cells three months ago—since then, his daily need for insulin has dropped by 90%. The treatment allows for the body to create insulin producing cells to replace the cells that are being destroyed because of how Type 1 diabetics autoimmune system operates.

“Suddenly, we have a different kind of therapy. You’re not just treating the symptom. You’re going after the root cause of the disease,” said Leiden.

Vertex is currently in its initial stages of the trial and the product will not be commercialized for a few years. The company announced that it will only be testing its treatment on the sickest diabetic patients because of how intense the treatment is on the patient’s immune system.

The New England Council recognizes the incredibly groundbreaking work Vertex is doing to help treat Type 1 diabetes.

Read more in the Boston Globe.

Recently from the Blog

NEC Announces COVID In-Person Event Policy; Plans Return to In-Person Programming in 2022

12/17/2021 | Read Post

NEC Partnership with internX to Expand Internship Opportunities for Minority Students

01/4/2022 | Read Post

In the News

NEC to Honor Historic All-Female Lineup of 2021 New Englanders of the Year

08/2/2021 | Read Press Release

NEC Board Elects Three New Directors

04/27/2021 | Read Press Release